News
Pfizer and Johnson & Johnson's Brewing Brawl Gets Real
Pfizer (NYSE: PFE) took direct aim at Johnson & Johnson (NYSE: JNJ) last year when it won FDA approval for Inflectra, a biosimilar to Johnson & Johnson's multi-billion dollar per year....
Alnylam Notches a Game-Changing RNAi Win
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is researching therapies that can treat genetic diseases by interfering with gene expression. Though Alnylam has yet to validate its approach with a....
Why Are Cancer Drugs So Expensive?
All drugs are costly to produce, but cancer drugs are notoriously expensive to push through to market, and every year, treatments get more and more expensive. In this clip from Industry Focus:....
Here's Why Quidel Corporation Stock Is Popping Today
Shares of Quidel Corporation (NASDAQ: QDEL), a molecular diagnostics specialist with a focus on quick turnarounds, ticked up 9.3% as of 11:26 a.m. EDT on Tuesday in response to a positive....
These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys?
These are the best times in a long time for three small biotechs. For two of them, these are the best times ever.Abeona Therapeutics (NASDAQ: ABEO), BeiGene (NASDAQ: BGNE), and Vanda....
3 Innovation-Forward Healthcare Stocks to Buy Now
Illumina (NASDAQ: ILMN), Mazor Robotics (NASDAQ: MZOR), and Novocure (NASDAQ: NVCR) are reshaping healthcare with innovative solutions that may produce market-beating returns for investors. Here's....
Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors
The year 2021 -- that's when Gilead Sciences (NASDAQ: GILD) thinks its acquisition of Kite Pharma (NASDAQ: KITE) will start to pay off. When Gilead announced plans to buy Kite, the company stated....
3 High-Yield Pharmaceutical Stocks
It can be tempting to buy stocks based solely on their dividend yield, but that can actually be a big mistake. However, that doesn't mean that all high-yield stocks should be avoided.So which big....
Why Bellicum Pharmaceuticals Stock Is Rising Today
Bellicum Pharmaceuticals (NASDAQ: BLCM), a clinical-stage biotech, saw its shares rise in excess of 11% today on almost three times the normal volume. The adoptive cell therapy company's stock....
3 Value Stocks for Smart Investors
Value investors know that getting a good stock at a good price can be difficult, particularly in markets like we face to day, but it's always worth it when you find one. They tend to offer the....
3 High-Yield Healthcare Stocks
One downside to a long-lasting bull market is that the market's dividend yield declines. That's a big problem for retirees who rely on their portfolio to meet their income needs.Even in today's....
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
There is perhaps no scarier word in the English language than "cancer." More than 15.5 million Americans who were alive as of Jan. 1, 2016, have had cancer at some point in their lives, according....
Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?
Billionaire George Soros is an iconic figure in the world of investing because of his unique ability to consistently beat the broader markets. As such, the quarterly 13F filings of his namesake....
3 Stocks to Hold for the Next Century
"Buy and hold" sounds like a simple investing strategy, but it only works if you're confident in your stocks for the very long haul. Titans topple all the time, and truly secular investments are....
Don't Make This Huge Mistake With Celgene
Several years ago, I started to look seriously at investing in Celgene (NASDAQ: CELG) stock. Someone I knew told me that I probably shouldn't get too excited about the biotech. I'm glad I didn't....
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Johnson & Johnson (NYSE: JNJ) reported anemic overall sales growth in the first half of 2017. The big healthcare company even saw a decline in year-over-year earnings during the period.....
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
You can call them "frenemies." Pfizer (NYSE: PFE) and Bristol-Myers Squibb (NYSE: BMY) are friends when it comes to blockbuster blood thinner Eliquis. But the two big pharma companies are enemies....
3 Stocks to Buy and Hold for Decades
Trading in and out of stocks may be exciting, but it's no way to build wealth. Buying shares of high-quality companies and holding on for the long haul is a far better alternative.We asked three....
Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?
Many healthcare stocks muddled along over the past week. That wasn't the case, though, for three stocks of companies operating in very different parts of the healthcare spectrum.Shares of Halozyme....
The Republicans Have a New Healthcare Proposal, but You'll Probably Still Hate It
When Donald Trump won the presidential election, the clock on the Affordable Care Act (ACA) began ticking and its repeal was all but a given in the minds of most Americans. Yet, nearly eight....
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
The global pharmaceutical industry is a giant, in case you didn't already know it. According to a 2016 report from the International Trade Administration (ITA), global sales of pharmaceuticals are....
The Smartest Move Johnson & Johnson Has Made All Year
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is what you might call a stalwart in the portfolios of risk-averse, income-seeking long-term investors. It's about as rock-solid as they....
Pfizer Punches Back at Johnson & Johnson in Prostate Cancer
After winning Food and Drug Administration (FDA) approval for use in castration-resistant metastatic prostate cancer in 2012, Pfizer's (NYSE: PFE) Xtandi quickly gained ground on Johnson &....
3 Reasons Why Gilead Sciences Stock Is a Buy Now
Gilead Sciences (NASDAQ: GILD) is a biotech behemoth, but its shares have fallen on tough times because hepatitis C sales are slipping. While headwinds in hepatitis C remain, the company's recent....
Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?
A head-to-head competition for market share in the renal cell carcinoma (RCC) market appears to be about to intensify. In one corner is Bristol-Myers Squibb (NYSE: BMY). With a market cap of over....